Today, the FDA released a new suite of resources to educate patients about biosimilars.
Today, the FDA released a new suite of resources to educate patients about biosimilars.
The new materials, “Biosimilars Basics for Patients,” explain that biosimilars are safe and effective medications that “are FDA-approved biologic medications that are compared to another medication—the original biologic.” The FDA describes biosimilars are being made “from natural sources” and developed “using advanced science.”
The resources explain that biosimilars can be expected to have the same benefits and risks, and that they may provide more treatment options, increase competition in the marketplace, and allow for lower costs.
The FDA also provides a brief overview of the ways in which it ensures that biosimilars are safe and effective, including reviewing data, monitoring drugs post-launch, and reviewing patient safety reports.
A frequently-asked-question (FAQ) section of the guide addresses questions such as how patients can tell whether they are receiving a biosimilar (the FDA suggests asking a doctor or pharmacist), whether it is safe to switch to a biosimilar (biosimilars can generally be used whether or not a patient has been first treated with a reference, says the guide), and whether individual patients can expect to see cost savings from biosimilars (health insurance plan providers are best situated to provide this information, according to the FAQ).
The FDA’s materials also include a “Biosimilar Basics” infographic and a one-page explanation of biosimilars that highlights the fact that “prescribers and patients should have no concerns about using these medications instead of reference products.”
The resources deliver on the Biosimilar Action Plan’s commitment to develop effective communications to improve upon the understanding of biosimilars among patients and other stakeholders. In the plan, the FDA committed to developing a “one-pager” for patients and to pursue video-format communications that can be disseminated on social media for patients and other key audiences.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.